From the July 2018 issue of HealthCare Business News magazine
Screen image from QView Medical's QVCAD
In December, QView Medical received FDA PMA approval for its QVCAD solution for use with the GE Invenia 3D ABUS automated breast ultrasound system. In March 2017, it received the CE Mark for use of the product with Siemens as well as GE.
The AI product is used for screening asymptomatic patients with dense breasts after a negative mammogram.
1st FDA Approved Handheld Wireless Ultrasound Probe.Currently being used to fight COVID-19 in Wuhan China, South Korea, & within the USA.Features include Lung Ultrasound Scanning, & PACS Compatibility. ( CONTACT US TODAY TO RESERVE INVENTORY )
CAD for mammography has become the standard of care, so it was natural for the company to develop a similar product, using deep learning for automated breast ultrasound exams, said Bob Foley, vice president of regulatory affairs and marketing strategy for QView Medical. Each ABUS exam leads to images with 2,000 slices, with a read time of five to eight minutes.
“We recognized there was a need to be able to read more productively,” Foley said.
Foley said the QVCAD is able to reduce reading time to approximately two minutes without compromising diagnostic accuracy.
Screenpoint Medical Transpara viewer
This Netherlands-based company recently released Transpara, an AI product that helps radiologists read mammograms and digital breast tomosynthesis, for use in Europe.
Nico Karssemeijer, the chief executive officer of Screenpoint Medical, said Transpara is different from CAD in that it provides more than a guide to the images.
“CAD systems are very limited because they only point out regions for radiologists to look at,” Karssemeijer said. “Our system interprets abnormalities and provides a cancer suspiciousness score for the whole mammogram that can be used as a second opinion. With the current release, we are reading mammograms as good as experienced radiologists.”
Karssemeijer stressed that the product is not intended to replace radiologists, noting that in the European market, two radiologists are required to read a mammogram.
“This is intended to partly replace one of the two,” Karssemeijer said. “There are some countries where there is a big shortage of radiologists. It’s only going to become more difficult with breast tomosynthesis. This is one of the big problems we have to solve before tomo is used for breast screening programs in Europe.”
The company is in the process of getting FDA clearance for Transpara and is currently doing clinical studies in the U.S.
Siemens MAMMOMAT Revelation
In March, Siemens Healthineers received FDA clearance for its MAMMOMAT Revelation, which was shown at RSNA 2017.
The premium mammography system features an integrated specimen imaging tool called InSpect, as well as a 3D tomo breast biopsy solution, the ability to perform contrast-enhanced mammography, and automated breast density measurement at the point of care.
“This option can save time, reduce costs and minimize the anxiety of being called back, especially where a woman might have to wait for an MR,” said Pam Cumming, senior director of product marketing for women's health at Siemens Healthineers North America. “It does give another nice option for people who don’t have easy access to MR.”
The MAMMOMAT Revelation also builds on the previous generation system, the MAMMOMAT Inspiration, with a wide, 50-degree field of view that allows better separation of overlapping breast tissue, resulting in improved visualization of subtle abnormalities, Cumming said.
“Overlapping tissue is a problem in mammography,” said Cumming, who noted that the depth resolution is 3.5 times higher than that of their competitors’ systems.
Cumming also noted that the wide angle might one day allow for reduced compression.
“Clinical data is saying you might not need to do as much compression,” Cumming said. “It’s the power of the wide angle that’s creating the basis for conversation and what might be possible.”
The MAMMOMAT Revelation also performs automated breast density measurement during the mammogram, instead of after the patient has left the imaging facility.
Volpara positioning feature
Volpara recently released a new software feature that provides feedback on how well the technologist did positioning the patient, by assigning mammographic studies into perfect, good, moderate and inadequate categories.
Training videos, which feature Louise Miller, co-founder of Mammography Educators, are embedded in the company's VolparaEnterprise software and will be based on exam statistics.
The software performs an automated assessment of positioning on every mammogram and will note, for example, if the technologist is not getting inframammary folds into the image, said Julian Marshall, Volpara’s chief product officer.
Since the feature is a quality control device, it doesn’t require FDA clearance.
The software, with cost depending on how big the facility is and how many mammograms it does, is designed to reduce the number of technical recalls, which facilities don’t receive reimbursement for.
“Our key products are being adopted by large health systems because they see it increasing quality across the system,” Marshall said.
Back to HCB News